Ischemic Stroke
Conditions
Keywords
Ischemic Stroke; cognitive impairment; gut microbiota
Brief summary
Post-stroke cognitive impairment(PSCI) is one of the most important factors causing disabilities after stroke. Recent study found that gut microbiota plays a key role in neurological diseases. Two recent small sample studies reported gut dysbiosis in PSCI patients. In order to further verify the relationship between PSCI and gut microbiota and the predictive value of gut microbiota and serum markers for cognitive impairment and poor prognosis after ischemic stroke. The study intended to collect stool specimens of patients with acute ischemic stroke and assess their cognitive psychological state, and to establish a prospective multi-center follow-up cohort to explore the correlation between the dynamic changes of intestinal flora in patients with stroke and PSCI and poor prognosis of stroke.
Interventions
None listed
Sponsors
Guangdong 999 Brain Hospital
Zhujiang Hospital
First Affiliated Hospital of Jinan University
Nanfang Hospital, Southern Medical University
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Inclusion criteria
* Meet the diagnostic criteria for acute ischemic stroke; * Aged between 18-75; * Onset within 7 days; * Sign informed consent and agree to provide relevant medical history data and biological specimens.
Exclusion criteria
* Patients diagnosed with TIA * Severe disturbance of consciousness (NIHSS consciousness score \> 1) * Previous severe mental disorders and dementia (AD8 score ≥ 2) * History of cerebral hemorrhage or any stroke within 12 months; * Serious systemic diseases including malignant tumors * Patients with aphasia and unable to cooperate to complete the Montreal Cognitive Assessment (MoCA) * ALT or AST greater than 2 times the upper limit of normal value or severe liver disease; * GFR less than 30mL/min/1.72m2 or severe kidney disease * Alcohol abused, drug use and chemical poisoning history (such as pesticide poisoning) * Patients with previous history of gastrointestinal tract or confirmed during hospitalization * Patients who could not collect stool samples within 4 days after admission.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Mini-Mental State Examination | 7 days after admission | A cognitive function screening test ranged 0-30, higher scores mean better cognitive function |
| Montreal Cognitive Assessment | 7 days after admission | A cognitive function screening test ranged 0-30, higher scores mean better cognitive function |
| Gut microbiota | 2 days after admission | Results of fecal bacteria by 16s RNA sequencing |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Trimethylamine-N-Oxide | 2 days after admission | A metabolites of gut microbiota in plasm, quantified by stable isotope dilution liquid chromatography tandem mass spectrometry |
| Modified Rankin Scale(mRS) | 7 days after admission | A neurological function score scale ranged 0-6, higher scores mean worse neurological outcome |
| Untargeted Metabolomics | 2 days after admission | Untargeted metabolomics refers to using gas chromatography-mass spectrometry (GC-MS) combined technique, without bias detection of all small molecule metabolites in plasma (mainly the relative molecular weight of 1000 Da endogenous small molecule compounds) levels. |
| National Institute of Health stroke scale(NIHSS) | Day 1 of admission | Neurological function score scale, ranged 0-42, higher scores mean more severe neurological deficit |
| Short chain fatty acids | 2 days after admission | A metabolites of gut microbiota from stool, detected by gas chromatography-mass spectrometry (GC-MS) combined technique |
Countries
China
Contacts
Primary ContactYin Jia, Master
Backup ContactZhang Mingsi, Master
Outcome results
None listed